InflaRx has filed a patent for humanized anti-C5a antibodies that specifically bind to a conformational epitope of human C5a. These antibodies can be used as active agents in pharmaceutical compositions for the treatment and prevention of diseases or disorders involving pathological C5a activity. GlobalData’s report on InflaRx gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on InflaRx, NSAID cancer drugs was a key innovation area identified from patents. InflaRx's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
The patent filed is for humanized anti-c5a antibodies
A recently filed patent (Publication Number: US20230279087A1) describes an antibody or antigen-binding fragment that can be used in medicine for the treatment or prevention of diseases or disorders involving pathological C5a activity. The antibody consists of a heavy chain variable domain (VH) and a light chain variable domain (VL). The VH domain has a specific amino acid sequence (SEQ ID NO: 10) or an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 10. The VL domain has a specific amino acid sequence (SEQ ID NO: 16) or an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 16. The antibody can also have one, two, or three amino acid substitutions in the VH domain or one, two, three, four, five, six, or seven amino acid substitutions in the VL domain.
The patent also mentions that the antibody can be a humanized antibody and can include a constant domain with specific amino acid exchanges. The antigen-binding fragment of the antibody can be selected from various types, including Fab fragments, Fab' fragments, F(ab')2 fragments, Fd fragments, Fv fragments, disulfide-linked Fvs (dsFv), single domain antibodies, and single chain Fv (scFv) antibodies.
The antibody or antigen-binding fragment exhibits properties such as a binding constant to C5a with a Kd value of 10 nM or less, at least 75% blocking activity for biological effects induced by one molecule C5a, no inhibition of CH50 activity in human plasma, and reduced immunogenicity compared to IFX-1.
The patent also covers a pharmaceutical composition comprising the antibody or antigen-binding fragment along with pharmaceutically acceptable carriers, diluents, excipients, and other ingredients. The antibody or antigen-binding fragment can be used in medicine for the treatment or prevention of various diseases or disorders involving pathological C5a activity, including autoimmune disorders, inflammatory disorders, cardiovascular or cerebrovascular disorders, bacterial or viral infections, neurodegenerative disorders, and cancers or precancerous conditions.
To know more about GlobalData’s detailed insights on InflaRx, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
